Redeye comments on Elicera reporting data from cohort 2 in the ongoing CARMA study. Encouragingly, four of six patients across the first two low-dose cohorts have achieved a complete metabolic response (CMR, no active disease). We are encouraged to see continued strong results at low dose levels. In addition, the Data Safety and Monitoring Board (DSMB) has recommended that the trial proceed as planned, enabling escalation into the third and final cohort at the highest dose level.
LÄS MER
